Inventor · disambiguated record
Hans Stauss
Also filed as: STAUSS HANS · STAUSS HANS J · STAUSS HANS JOSEF
13 granted patents·14 pending applications·126 citations·filing 1997–2025
90Inventor score
Files withUCL BUSINESS LTD9IMP INNOVATIONS LTD3STAUSS HANS3UCL BUSINESS PLC3GANYMED PHARMACEUTICALS AG2
Top patents by PatentIndex Score
27 records- 0189US9624292B2Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bondsVOSS RALF-HOLGER·Filed 2012·Granted Apr 18, 2017·23 cites·10 claims
- 0283US6805861B2Immunotherapy using cytotoxic T lymphocytes (CTL)IMP COLLEGE INNOVATIONS LTD·Filed 1997·Granted Oct 19, 2004·61 cites·12 claims
- 0382US8529904B2Immunotherapeutic methods using epitopes of WT-1 and GATA-1STAUSS HANS JOSEF·Filed 2007·Granted Sep 10, 2013·9 cites·8 claims
- 0481US7326767B1Immunotherapeutic methods using epitopes of WT-1 and GATA-1GANYMED PHARMACEUTICALS AG·Filed 2000·Granted Feb 5, 2008·16 cites·4 claims
- 0579US8722048B2T-cell receptor capable of recognising an antigen from cytomegalovirusSTAUSS HANS·Filed 2010·Granted May 13, 2014·5 cites·4 claims
- 0678US11643451B2T cell receptorUCL BUSINESS LTD·Filed 2017·Granted May 9, 2023·3 cites·11 claims
- 0778US2024384301A1Method for enhancing the suppressive properties of treg cellsUCL BUSINESS LTD·Filed 2024·Application pending·0 cites
- 0875US12227756B2Engineered regulatory T cellUCL BUSINESS LTD·Filed 2019·Granted Feb 18, 2025·1 cites·11 claims
- 0970US7951783B2Therapeutically useful moleculesIMP INNOVATIONS LTD·Filed 2004·Granted May 31, 2011·4 cites·11 claims
- 1069US12077774B2Method for enhancing the suppressive properties of Treg cellsUCL BUSINESS LTD·Filed 2019·Granted Sep 3, 2024·0 cites·10 claims
- 1168US8889141B2T-cell receptorSTAUSS HANS·Filed 2010·Granted Nov 18, 2014·4 cites·6 claims
- 1261US12378298B2T cell receptorUCL BUSINESS LTD·Filed 2021·Granted Aug 5, 2025·0 cites·3 claims
- 1361US9732141B2Therapeutically useful moleculesIMP INNOVATIONS LTD·Filed 2014·Granted Aug 15, 2017·0 cites·15 claims
- 1461US2025154532A1Engineered regulatory t cellUCL BUSINESS LTD·Filed 2025·Application pending·0 cites
- 1553US2014199762A1Immunotherapeutic Methods Using Epitopes of WT-1 and GATA-1GANYMED PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 1652US10450360B2Therapeutically useful moleculesIMPERIAL INNOVATIONS LTD·Filed 2016·Granted Oct 22, 2019·0 cites·3 claims
- 1752US2011274675A1Therapeutically Useful MoleculesIMP INNOVATIONS LTD·Filed 2011·Application pending·0 cites
- 1851US2022364057A1Engineered regulatory t cellUCL BUSINESS LTD·Filed 2020·Application pending·0 cites
- 1950US2022267406A1MethodUCL BUSINESS LTD·Filed 2020·Application pending·0 cites
- 2048US2022363733A1Engineered regulatory t cellUCL Busines Ltd·Filed 2020·Application pending·0 cites
- 2147US2023226182A1Chimeric antigen receptor specific for hlaUCL BUSINESS LTD·Filed 2020·Application pending·0 cites
- 2245US2017327596A1MethodUCL BUSINESS PLC·Filed 2017·Application pending·0 cites
- 2345US2017198029A1Single chain antigen recognizing constructs (scarcs) stabilized by the introduction of novel disulfide bondsUNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ·Filed 2017·Application pending·0 cites
- 2444US2018251513A1T cell receptorUCL BUSINESS PLC·Filed 2016·Application pending·0 cites
- 2543US2014134720A1MethodSTAUSS HANS·Filed 2012·Application pending·0 cites
- 2642US2003103946A1Immunotherapeutic methods and moleculesIMP COLLEGE INNOVATIONS LTD·Filed 2001·Application pending·0 cites
- 2734US2019336531A1Natural killer t (nkt) cells comprising engineered t cell receptorsUCL BUSINESS PLC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hans Stauss files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →